(City)

FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

(State)

(Zip)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 |
|-------------|------|-------|
|-------------|------|-------|

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| STATEMENT OF CHANGES IN BENEFICIAL | OWNERSHIP |
|------------------------------------|-----------|
| | |

OMB APPROVAL 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

| | | | or Section 30(h) of the Investment Company Act of 1940 | | | | | |
|--|---------------------|----------|--|-----------------------|--|-----------------------|--|--|
| 1. Name and Address of Reporting Person* Alpern Robert J | | | 2. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ABBV] | | lationship of Reporting Person(s) to Issuer ck all applicable) Director 10% Owner | | | |
| (Last) 1 N. WAUKE | (First) GAN ROAD | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 12/31/2022 | | Officer (give title below) | Other (specify below) | | |
| (Street) NORTH CHICAGO | IL | 60064 | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Indi Line) X | vidual or Joint/Group Fil Form filed by One Re Form filed by More the Person | eporting Person | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 2. Transaction 2A. Deemed 5. Amount of 7. Nature 1. Title of Security (Instr. 3) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) Date (Month/Day/Year) Securities Beneficially Owned Following of Indirect Beneficial **Execution Date** if any Code (Instr. 8) (Month/Day/Year) Ownership Reported Transaction(s) (Instr. 4) (A) or (D) Price Code Amount (Instr. 3 and 4)

| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | |
|--|---|--|---|------------------------------|---|-----|-----|-------------------------------------|--------------------|--|--|---|--|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transa Code (8) | | | | Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Stock Equivalent Units | \$161.61 | 12/31/2022 | | A | | 46 | | (1) | (2) | Common Stock | 46 | \$161.61 | 8,723 ⁽³⁾ | D | |

Explanation of Responses:

- 1. Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
- 2. Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
- 3. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Steven L. Scrogham, attorneyin-fact for Robert J. Alpern

01/03/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.